Tharimmune (THAR) Stock News & Updates | StockTitan
stocktitan.net · Read at source ↗
Key milestones include Super Validator approval, board additions, and commitment to quarterly ecosystem reporting to support institutional Canton Network adoption. ... Tharimmune (NASDAQ: THAR) announced leadership changes effective Feb 5, 2026: Mark Wendland was elected Chairman of the Board ...
Tharimmune changed its name to Canton Strategic Holdings, Inc. and switched its Nasdaq ticker from THAR to CNTN on February 18, 2026, reflecting its move toward a Canton Network-focused digital asset treasury strategy alongside clinical-stage biotechnology research and development.
Rebrand follows Canton treasury launch
The company announced the rebrand on February 17, 2026, following the launch of its digital asset treasury strategy in November 2025 through a $545 million private placement. A subsequent $55 million registered offering provided additional funding.
The strategy encompasses Canton Coin (CC) acquisitions, Super Validator operations and investments in Canton-based applications intended to support institutional adoption. Company updates also cover Canton Foundation governance participation, blockchain market infrastructure, financing and leadership changes.
In its December disclosures, Tharimmune said it had acquired Canton Coin and described itself as the first publicly traded company to leverage CC. It also identified itself as the first publicly traded company supported by the Canton Foundation.
The rebrand announcement highlighted Super Validator approval, board appointments and a commitment to quarterly ecosystem reporting.
January offering raises approximately $55 million
Tharimmune priced a $55 million underwritten registered offering on January 20, 2026. At pricing, it expected the transaction to close on or about January 21, subject to customary closing conditions. The company announced the closing of the underwritten registered direct offering on January 22.
The transaction comprised:
- 1,800,000 common shares priced at $2.92 each.
- Pre-funded warrants covering up to 17,000,000 common shares, priced at $2.9199 per warrant.
- Approximately $55 million in gross proceeds, before underwriting discounts, commissions and offering expenses.
Proceeds were designated for expansion of the Canton-centric treasury strategy and general corporate working capital. Clear Street served as sole bookrunning manager.
The offering used a shelf registration statement, File No. 333-292648, filed with the SEC on January 9, 2026, and effective January 16. A prospectus supplement was filed January 20.
Board and executive appointments support the strategy
The company announced several leadership changes between December 2025 and February 2026.
- Jacob Asbury became chief financial officer effective December 12, 2025. His responsibilities include capital planning, treasury management, financial reporting and expansion of the Canton Coin treasury infrastructure. The company cited nearly two decades of experience, including CFO positions at Clear Street Group, Performance Flight & Custom Jet Charters, and Instinet. He holds a B.S. from the University of Vermont. At the time of his appointment, Tharimmune was applying to become a Super Validator and investing in Canton Network applications.
- Jill Sommers and William Wiley, CFA, joined the board effective February 1, 2026, with the appointments announced February 2. The company said their regulatory and capital-markets leadership would strengthen governance and support its Canton strategy, including CC acquisitions, Super Validator operations and institutional adoption of blockchain-enabled market infrastructure.
- Mark Wendland was elected board chairman and Angela Radkowski was appointed chief operating officer effective February 5, 2026, according to a February 6 announcement. Vincent LoPriore moved from chairman to a board-member role. Radkowski, whose prior experience includes DRW and Citadel, was assigned responsibility for operations, the quarterly Canton Network research initiative and Super Validator activation.
The February leadership announcement reaffirmed the company’s plans to acquire CC, operate a Super Validator and invest in Canton-based applications.
Super Validator approval and institutional network activity
Tharimmune received approval to operate a Canton Network Super Validator on January 26, 2026. The role allows it to help secure transactions and earn Canton Coin rewards for its digital asset treasury.
The company said it would publish quarterly research covering onchain analytics, governance, tokenomics and roadmap developments, and hold quarterly public webinars for ecosystem participants. Its announcement cited more than 700,000 daily transactions and $9 trillion in monthly transaction volume supported by Canton Network Super Validators.
Earlier, on December 18, 2025, Tharimmune commented on the DTCC and Digital Asset partnership announced that day to tokenize U.S. Treasury securities on Canton. It pointed to approximately $30 trillion in U.S. Treasuries under DTCC custody, alongside Canton’s transaction figures, as evidence of institutional blockchain adoption. At that stage, it was pursuing Super Validator and application-investor roles.
The source’s news listing also included Tradeweb’s February 5, 2026, release of fourth-quarter and full-year 2025 financial results. The summary reported:
- Fourth-quarter revenue of $521.2 million, up 12.5%.
- Average daily volume of $2.8 trillion, up 23.3%.
- Fourth-quarter net income of $367.1 million, up 129.5%, including $205.4 million in non-operating Canton Coin gains.
- A quarterly cash dividend increase of 16.7%, to $0.14.
- Authorization of a $500 million share repurchase program.
TH104 development continues alongside digital assets
Tharimmune’s biotechnology disclosures included a November 13, 2025, update on TH104, its nalmefene buccal film prophylaxis program targeting respiratory depression caused by fentanyl and ultrapotent opioids.
Following a Type D meeting, the company reported positive FDA feedback on its pharmacokinetic simulation modeling plan. The agency agreed with the proposed modeling approach and provided technical guidance for the final plan, supporting the company’s intended pathway toward a 505(b)(2) new drug application.
Tharimmune also said it was initiating a chemistry, manufacturing and controls plan to scale production and maintain product quality for advanced development.
The pharmacokinetic simulations projected approximately 30 minutes to reach the target concentration and about 24 hours of sustained protective levels. The update contrasted those projections with current naloxone effects lasting 30–90 minutes.
Historical quote and listed end-of-day changes
The source listed THAR’s last closing price as $4.74 and noted that the company now trades as CNTN.
Its individual news entries displayed the following end-of-day percentage changes:
- February 17, 2026 — rebrand: +5.80%.
- February 6, 2026 — chairman and COO appointments: +5.34%.
- February 5, 2026 — Tradeweb results entry: −16.91%.
- February 2, 2026 — board appointments: +12.07%.
- January 26, 2026 — Super Validator approval: +9.12%.
- January 22, 2026 — offering closing: −1.66%.
- January 20, 2026 — offering pricing: 0.00%.
- December 18, 2025 — DTCC initiative statement: −5.93%.
- December 12, 2025 — CFO appointment: −5.53%.
- November 13, 2025 — TH104 FDA feedback: −6.52%.
Sources & attribution
- Published
- Feb 17, 2026 · 12:10 PM UTC
- Source
- stocktitan.net
- Publisher
- stocktitan.net
- Source URL
- https://www.stocktitan.net/news/THAR/
Full attribution under the Digital Millennium Copyright Act (DMCA), 17 U.S.C. § 512: this article is an original report by Canton Intelligence that summarizes the reporting of the publishers named above, links to their original work, and reproduces no protected expression beyond brief factual reference and in-line attribution (“according to stocktitan.net”). All rights in the underlying reporting remain with the publishers listed; nothing here implies endorsement by or affiliation with them. Rights holders may request correction, update or removal through the contact address published at infiniti.w3ai.io.